Cargando…
Cardiovascular Injury Due to SARS-CoV-2
PURPOSE OF REVIEW: The world is currently facing the largest global health crisis since the early 1900s due to a novel coronavirus. While SARS-CoV-2 infection causes predictable symptoms in COVID-19 patients, including upper respiratory distress and fever, the heterogeneity of manifestations is surp...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934983/ https://www.ncbi.nlm.nih.gov/pubmed/33717830 http://dx.doi.org/10.1007/s40588-021-00160-0 |
_version_ | 1783660922035765248 |
---|---|
author | Bugert, Christina L. Kwiat, Victoria Valera, Isela C. Bugert, Joachim J. Parvatiyar, Michelle S. |
author_facet | Bugert, Christina L. Kwiat, Victoria Valera, Isela C. Bugert, Joachim J. Parvatiyar, Michelle S. |
author_sort | Bugert, Christina L. |
collection | PubMed |
description | PURPOSE OF REVIEW: The world is currently facing the largest global health crisis since the early 1900s due to a novel coronavirus. While SARS-CoV-2 infection causes predictable symptoms in COVID-19 patients, including upper respiratory distress and fever, the heterogeneity of manifestations is surprising. This review focuses on direct and indirect causes of myocardial injury in COVID-19 patients and highlights current knowledge, treatment strategies, and outstanding questions in the field. RECENT FINDINGS: Data are emerging that highlight the extent of cardiovascular involvement in COVID-19 patients, including evidence that SARS-CoV-2 causes myocarditis and increases cardiac risk. The incidence of cardiac injury is much greater in patients with severe disease presentation and those in intensive care. SUMMARY: During the past year, COVID-19 patient mortality rates have improved due to tailored pharmacological treatments and patient management strategies that address the unique presentation of symptoms, which will hopefully also reduce the incidence of cardiac injury. |
format | Online Article Text |
id | pubmed-7934983 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-79349832021-03-08 Cardiovascular Injury Due to SARS-CoV-2 Bugert, Christina L. Kwiat, Victoria Valera, Isela C. Bugert, Joachim J. Parvatiyar, Michelle S. Curr Clin Microbiol Rep Virology (S Li and K Parvatiyar, Section Editors) PURPOSE OF REVIEW: The world is currently facing the largest global health crisis since the early 1900s due to a novel coronavirus. While SARS-CoV-2 infection causes predictable symptoms in COVID-19 patients, including upper respiratory distress and fever, the heterogeneity of manifestations is surprising. This review focuses on direct and indirect causes of myocardial injury in COVID-19 patients and highlights current knowledge, treatment strategies, and outstanding questions in the field. RECENT FINDINGS: Data are emerging that highlight the extent of cardiovascular involvement in COVID-19 patients, including evidence that SARS-CoV-2 causes myocarditis and increases cardiac risk. The incidence of cardiac injury is much greater in patients with severe disease presentation and those in intensive care. SUMMARY: During the past year, COVID-19 patient mortality rates have improved due to tailored pharmacological treatments and patient management strategies that address the unique presentation of symptoms, which will hopefully also reduce the incidence of cardiac injury. Springer International Publishing 2021-03-05 2021 /pmc/articles/PMC7934983/ /pubmed/33717830 http://dx.doi.org/10.1007/s40588-021-00160-0 Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Virology (S Li and K Parvatiyar, Section Editors) Bugert, Christina L. Kwiat, Victoria Valera, Isela C. Bugert, Joachim J. Parvatiyar, Michelle S. Cardiovascular Injury Due to SARS-CoV-2 |
title | Cardiovascular Injury Due to SARS-CoV-2 |
title_full | Cardiovascular Injury Due to SARS-CoV-2 |
title_fullStr | Cardiovascular Injury Due to SARS-CoV-2 |
title_full_unstemmed | Cardiovascular Injury Due to SARS-CoV-2 |
title_short | Cardiovascular Injury Due to SARS-CoV-2 |
title_sort | cardiovascular injury due to sars-cov-2 |
topic | Virology (S Li and K Parvatiyar, Section Editors) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934983/ https://www.ncbi.nlm.nih.gov/pubmed/33717830 http://dx.doi.org/10.1007/s40588-021-00160-0 |
work_keys_str_mv | AT bugertchristinal cardiovascularinjuryduetosarscov2 AT kwiatvictoria cardiovascularinjuryduetosarscov2 AT valeraiselac cardiovascularinjuryduetosarscov2 AT bugertjoachimj cardiovascularinjuryduetosarscov2 AT parvatiyarmichelles cardiovascularinjuryduetosarscov2 |